Gut

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
Published Online First: 4 May 2005. doi:10.1136/gut.2005.065136
Gut 2005;54:1610-1614
Copyright © 2005 BMJ Publishing Group Ltd & British Society of Gastroenterology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
gut.2005.065136v1
54/11/1610    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yuen, M-F
Right arrow Articles by Lai, C-L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yuen, M-F
Right arrow Articles by Lai, C-L
Topic Collections
Right arrowRelevant Articles

HEPATITIS

Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications

M-F Yuen, H-J Yuan, D K-H Wong, J C-H Yuen, W-M Wong, A O-O Chan, B C-Y Wong, K-C Lai, C-L Lai

Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong

Correspondence to:
Correspondence to:
Professor C-L Lai
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Rd, Hong Kong, China; hrmelcl{at}hkucc.hku.hk


ABSTRACT
Background: Identifying risk factors for the development of complications of chronic hepatitis B (CHB) is important for setting up treatment criteria.

Aim: To determine risk factors for the development of complications in Asian CHB patients.

Patients and methods: A total of 3233 Chinese CHB patients (mean follow up 46.8 months) were monitored for liver biochemistry, viral serology, hepatitis B virus (HBV) DNA levels, acute exacerbation, hepatitis B e antigen (HBeAg) seroconversion, and development of cirrhotic complications and hepatocellular carcinoma.

Results: Median age for HBeAg seroconversion and development of complications was 35 years and 57.2 years, respectively. Patients with alanine aminotransferase (ALT) levels of 0.5–1 times the upper limit of normal (ULN) and 1–2x ULN had an increased risk for the development of complications compared with patients with ALT levels <0.5x ULN (p<0.0001 for both). HBeAg/antibody to hepatitis B e antigen status, and number of episodes, duration, and peak ALT levels of acute exacerbations were not associated with an increased risk of complications. In patients with complications, 43.6% had HBV DNA levels less than 1.42x105 copies/ml. Male sex, stigmata of chronic liver disease, old age, low albumin, and high {alpha} fetoprotein levels on presentation were independently associated with increased cumulative risk of complications. Male sex, presence of hepatitis symptoms, old age, low albumin level, and presence of complications on presentation were independently associated with shorter survival.

Conclusion: Prolonged low level viraemia causing insidious and continual liver damage, as reflected by ALT levels of 0.5–2x ULN, is the most likely pathway for the development of complications in Asian CHB patients.

Abbreviations: CHB, chronic hepatitis B; HBV, hepatitis B virus; ALT, alanine aminotransferase; ULN, upper limit of normal; HCC, hepatocellular carcinoma; HBeAg, hepatitis B e antigen; SBP, spontaneous bacterial peritonitis; anti-HBe, antibody to hepatitis B e antigen; AFP, {alpha} fetoprotein; PCR, polymerase chain reaction

Keywords: HBeAg seroconversion; alanine aminotransferase; cirrhosis related complications; hepatocellular carcinoma; survival


Relevant Articles

Do baseline ALT levels predict complications of chronic hepatitis B? • Authors’ reply
T-I Huo, J-C Wu, S-D Lee, M-F Yuen, and C-L Lai
Gut 2006 55: 745-746. [Extract] [Full Text] [PDF]

Predicting survival in hepatitis B
M Sherman
Gut 2005 54: 1521-1523. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 NEJMHome page
C.-L. Lai and M.-F. Yuen
Chronic Hepatitis B -- New Goals, New Treatment
N. Engl. J. Med., December 4, 2008; 359(23): 2488 - 2491.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
N. A. Singh and N. Reau
Management of hepatitis B virus
J. Antimicrob. Chemother., August 1, 2008; 62(2): 224 - 228.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C.-L. Lai, E. Gane, Y.-F. Liaw, C.-W. Hsu, S. Thongsawat, Y. Wang, Y. Chen, E. J. Heathcote, J. Rasenack, N. Bzowej, et al.
Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B
N. Engl. J. Med., December 20, 2007; 357(25): 2576 - 2588.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
C.-L. Lai and M.-F. Yuen
The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points
Ann Intern Med, July 3, 2007; 147(1): 58 - 61.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
B. Degertekin and A. S.F. Lok
When to Start and Stop Hepatitis B Treatment: Can One Set of Criteria Apply to All Patients Regardless of Age at Infection?
Ann Intern Med, July 3, 2007; 147(1): 62 - 64.
[Full Text] [PDF]

Home page
 GutHome page
M Sherman
Predicting survival in hepatitis B
Gut, November 1, 2005; 54(11): 1521 - 1523.
[Full Text] [PDF]

eLetters:

Read all eLetters

Do baseline ALT levels predict complications of chronic hepatitis B?
Teh-Ia Huo, et al.
Gut Online, 24 Oct 2005 [Full text]
Re: Do baseline ALT levels predict complications of chronic hepatitis B?
Ching-Lung Lai, et al.
Gut Online, 14 Nov 2005 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 BMJ Publishing Group Ltd & British Society of Gastroenterology